

Lawrence Panasci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4857188/publications.pdf>

Version: 2024-02-01

22
papers

1,258
citations

623188

14
h-index

676716

22
g-index

22
all docs

22
docs citations

22
times ranked

2224
citing authors

#	ARTICLE	IF	CITATIONS
1	Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2016, 388, 2997-3005.	6.3	435
2	Epstein-barr virus related lymphoepithelioma-like carcinoma of lung. <i>Journal of Surgical Oncology</i> , 1987, 36, 280-283.	0.8	192
3	Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond. <i>Frontiers in Pharmacology</i> , 2013, 4, 5.	1.6	131
4	Precision spherical nucleic acids for delivery of anticancer drugs. <i>Chemical Science</i> , 2017, 8, 6218-6229.	3.7	84
5	Xrcc3 Induces Cisplatin Resistance by Stimulation of Rad51-Related Recombinational Repair, S-Phase Checkpoint Activation, and Reduced Apoptosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 495-505.	1.3	66
6	The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. <i>Investigational New Drugs</i> , 2013, 31, 461-468.	1.2	51
7	Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. <i>Investigational New Drugs</i> , 2012, 30, 1248-1256.	1.2	45
8	Dose-Response Trial of Megestrol Acetate in Advanced Breast Cancer: Cancer and Leukemia Group B Phase III Study 8741. <i>Journal of Clinical Oncology</i> , 1999, 17, 64-64.	0.8	42
9	The role of DNA repair in nitrogen mustard drug resistance. <i>Anti-Cancer Drugs</i> , 2002, 13, 211-220.	0.7	39
10	Interferon- β enhances temozolomide activity against MGMT-positive glioma stem-like cells. <i>Oncology Reports</i> , 2015, 34, 2715-2721.	1.2	32
11	Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, 135-140.	1.0	28
12	Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells. <i>Investigational New Drugs</i> , 2012, 30, 1736-1742.	1.2	23
13	PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 23-32.	1.1	21
14	Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan. <i>Frontiers in Pharmacology</i> , 2015, 6, 147.	1.6	17
15	Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy. <i>Leukemia Research</i> , 2011, 35, 1080-1086.	0.4	13
16	Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 457-460.	1.1	11
17	Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014204287-bcr2014204287.	0.2	6
18	IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1653-1659.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016215525.	0.2	5
20	Combination chemotherapy with carboplatin and bleomycin for advanced and recurrent head and neck cancer: A phase II study. <i>Journal of Surgical Oncology</i> , 1988, 39, 215-216.	0.8	4
21	The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature. <i>Cancer Reports</i> , 2022, 5, e1531.	0.6	4
22	Alteration of the systemic antitumor activity of melphalan by sodium cyanate in MOPC-460D myeloma-bearing BALB/C mice. <i>Journal of Surgical Oncology</i> , 1993, 52, 110-114.	0.8	3